54 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private … Administration (“TGA”), the Department of Health and Human Services, the European Commission, the European Medicines Agency (“EMA”) or any other Health
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
an exemption. The withholding obligations under FATCA generally apply to dividends on our common stock. The U.S. Department of the Treasury has issued
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
under FATCA generally apply to dividends on our common stock. The U.S. Department of the Treasury has issued proposed Treasury Regulations providing
8-K
EX-10.1
CGTX
Cognition Therapeutics Inc
1 May 23
Departure of Directors or Certain Officers
7:30am
, to the attention of its Legal Department at the address of its principal executive office; or (c) or at such other address as may have been furnished
8-K
EX-10.1
74u5o7xd4b2jho3ebyn
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
EX-1.2
407t4m76 4ekxa926s5
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
xfm3rohimbq5
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
vmg2fkxg69u27 88
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
dva8 cp74c8akyga7hh
20 Oct 22
Draft registration statement
12:00am
10-K
muj8og4 b29op6qx768j
30 Mar 22
Annual report
7:40am
8-K
EX-99.2
rn00lx2ygguvz
15 Mar 22
Regulation FD Disclosure
9:32am
424B4
s7c7x
12 Oct 21
Prospectus supplement with pricing info
4:11pm